TITLE

Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by the CHART Steering Committee

AUTHOR(S)
Dische, S.; Gibson, D.; Parmar, M.; Saunders, M. I.
PUB. DATE
December 1996
SOURCE
Thorax;Dec1996, Vol. 51 Issue 12, p1262
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66084916

 

Related Articles

  • Chimioradiothérapie néoadjuvante des cancers bronchopulmonaires non à petites cellules. Girard, N.; Hennequin, C.; Mornex, F. // Oncologie;Jun2007, Vol. 9 Issue 6, p475 

    Combined surgery and radiotherapy has become a standard treatment regimen for patients with multiple cancers. For non-small cell lung cancer, however, this strategy is currently used only in clinical trial settings because of its high metastatic potential, which reduces the effectiveness of...

  • Imaging metrics predicted OS in NSCLC treated with stereotactic ablative radiotherapy.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p32 

    The article reports that positron emission tomography/computed tomography imaging before treatment can help predict the survival chances of patients with non-small cell lung cancer treated with stereotactic ablative radiotherapy.

  • Thoracic Radiotherapy Does Not Prolong Survival in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Johnson, David H.; Einhorn, Lawrence H.; Bartolucci, Alfred; Birch, Robert; Omura, George; Perez, Carlos A.; Greco, F. Anthony // Annals of Internal Medicine;7/1/90, Vol. 113 Issue 1, p33 

    Compares the survival of patients with locally advanced non-small cell lung cancer treated with single-agent vindesine, thoracic radiotherapy, or both treatment modalities. Characteristics of the patients; Response to induction therapy; Adequacy of radiotherapy.

  • Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. Falk, Stephen J; Girling, David J; White, Roger J; Hopwood, Penelope; Harvey, Angela; Qian, Wendi; Stephens, Richard J // BMJ: British Medical Journal (International Edition);8/31/2002, Vol. 325 Issue 7362, p465 

    Abstract Objective: To determine whether patients with locally advanced non-small cell lung cancer unsuitable for resection or radical radiotherapy, and with minimal thoracic symptoms, should be given palliative thoracic radiotherapy immediately or as needed to treat symptoms. Design:...

  • The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study. Kasymjanova, G.; Grossman, M.; Tran, T.; Jagoe, R. T.; Cohen, V.; Pepe, C.; Small, D.; Agulnik, J. // Current Oncology;Jun2013, Vol. 20 Issue 3, p152 

    Background Most lung cancer patients experience multiple symptoms related either to the disease or its treatment. The commonly reported symptoms are pain, depression, anxiety, nausea, and poor well-being. The aim of the present study was to evaluate the effect of acupuncture as a potential...

  • Treatment of advanced non-small cell lung cancer. Hansen, Heine H // BMJ: British Medical Journal (International Edition);8/31/2002, Vol. 325 Issue 7362, p452 

    Editorial. Focuses on the idea that treatment of advanced non-small cell lung cancer should include palliative radiotherapy. Mention of research on treatments such as fractionated thoracic irradiation and combination chemotherapy with cisplatin; Suggestion that the pros and cons of treatments...

  • Erlotinib marginally cost-effective.  // British Journal of Hospital Medicine (17508460);Mar2010, Vol. 71 Issue 3, p129 

    The article reports on the cost-effectiveness of erlotinib for the treatment of patients with advanced non-small cell lung cancer.

  • Accelerated Sequential Radiotherapy and Survival in NSCLC. Nichols, Emma Hitt // MD Conference Express;Jun2014, Vol. 14 Issue 3, p15 

    Shorter overall treatment time with radiotherapy (RT) appears to improve outcomes in patients with non—small cell lung cancer (NSCLC) compared with longer overall treatment time. This article outlines optimal RT dose and fractionation for concurrent and sequential schedules for stage III...

  • Erlotinib.  // Reactions Weekly;11/22/2008, Issue 1229, p12 

    The article describes the case of a 74-year-old man who developed fatal diarrhoea during treatment with erlotinib for metastatic non-small cell lung cancer and concomitant split-course hypofractionated radiotherapy. The patient, who was a smoker, developed a grade 1 skin rash three weeks after...

  • Outcome and treatment strategy in female lung cancer: a single institution experience. Cicėnas, S.; Kurtinaitis, J.; Smailytė, G. // Advances in Medical Sciences (De Gruyter Open);2010, Vol. 55 Issue 2, p273 

    Purpose: To assess the survival rate of female lung cancer treated at the Institute of Oncology of the Vilnius University, Lithuania during the period between 1996-2005.Materials and Methods: During the period between 1996-2005, 471 women diagnosed with lung cancer were treated at the Department...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics